Objective. Multimodal analgesia and analgesics with different modes of action can reduce perioperative opioid demand and their undesirable side effects. In our study we presumed that patients anesthetised with additional perioperative dexmedetomidine infusion, during radical prostatectomy, would need less opioids during and after surgery compared to the control group. Materials and methods. 40 patients, 18-80 years of age, ASA class 1-3 (American Society of Anesthesiologists), scheduled for radical prostatectomy, were included in the study. Patients were randomly divided into two groups (20 pts in each group). In both groups, fentanyl in repeated boluses was used as an analgesic; in the studied group, an additional infusion of dexmedetomidine (0.3 µg/kg/h) was started with intravenous line insertion and continued until the beginning of wound closure. Analgesic consumption during the operation, in the post-anaesthesia care unit, in the Intensive Care Unit on the day of the operation and on the first postoperative day was recorded. Results. The patients with perioperative dexmedetomidine infusion were slightly younger (p=0.007), also the duration of their surgery was shorter (p =0.05). Differences in opioid consumption between the groups were not found. Also, pain assessment, by visual analogue scale (VAS) after 12, 18, 24, 30, 36 and 42 hours, was not statistically different between groups. Conclusion. In our study, perioperative dexmadetomidine did not reduce periand postoperative opioid consumption. Also, undesirable dexmedetomidine side effects, such as bradycardia and hypotension, were not observed.
INTRODUCTION
Radical prostatectomy is one of the extensive urological procedures associated with strong postoperative pain and a hormonal and metabolic stress response, which can lead to cardiovascular complications, increased occurrence of postoperative paralytic ileus, weakening of the immune response, and changes in carbohydrate and protein metabolism. (1) Optimal perioperative pain management is therefore necessary to inhibit injury triggered pain transfer and reduce the autonomous and somatic pain response. (2) For postoperative analgesia, an epidural catheter can be used. If there are contraindications or if an epidural catheter cannot be inserted, continuous intravenous infusion of piritramide (patient controlled analgesia, PCA) can be used. (3, 4) Epidural analgesia reduces the endocrine and metabolic stress response, facilitates early gut mobility, decreases wound infections and postoperative respiratory complications. (3, (5) (6) (7) (8) (9) Given that epidural catheter insertion is an invasive method associated with complications, and that prostatic cancer patients are older, often with comorbidites, degenerative spine changes and on anticoagulants, this method is often avoided. (10) Only opioid based pain relief is associated with adverse reactions (insufficient breathing, nausea, vomiting, constipation, ileus, drowsiness); also, acute tolerance to opioids may develop intraoperatively. (11) (12) (13) Multimodal analgesia is the most appropriate method for postoperative pain relief after radical prostatectomy. Pain relief is more effective and opioid side effects are minimized. (2) Combination of opioids, nonopioid analgesics and analgesics with a different mode of action, dexmedetomidine, reduce opioid consumption and their side effects during and after surgery. (14) (15) (16) (17) (18) (19) (20) (21) Dexmedetomidine binds onto α2 adrenergic receptors in the locus ceruleus and posterior horns of the spinal cord. It also inhibits the transfer of pain stimulus and reduces the release of norepinephrine. It acts simpaticolitically and therefore reduces mean arterial pressure and heart rate. It also works as an analgesic, hypnotic and anxiolytic drug, and does not inhibit breathing. (15) (16) (17) (18) 22) Due to the analgesic effect of dexmedetomidine, the need for additional opioids is reduced, there is less breathing depression, nausea and vomiting, bowel function is less affected and recovery is faster. (15, (19) (20) (21) Dexmedetomidine acts also as an antiinflammatory agent. It inhibits the sympathetic nervous system and stimulates the parasympathetic nervous system, which reduces peripheral proinflammatory cytokine secretion. (23, 24, 26 ) The aim of our study was to find out if an intraoperative dexmedetomidine infusion reduces the consumption of opioid analgesics and to study the side effects during and after radical prostatectomy.
MATERIALS AND METHODS

Subjects
This prospective study included 40 patients, aged 18 to 80 years, classified according to the American Society of Anaesthesiologists (ASA) into groups 1-3, scheduled for radical prostatectomy. Prior to the operation, patients gave their signed consent for participation in the study and for anaesthesia and surgery. The study protocol was approved by the Medical Ethics Committee of the Republic of Slovenia, at the Ministry of Health of the Republic of Slovenia (KME 54/07/15). Patients with allergies to α2 agonists,, uncontrolled arterial hypertension, the presence of a 2nd or 3rd degree AV block and SIGNA VITAE 2017; 13(2): 102-107 without signed consent to participate, were excluded from the study. Patients were randomly allocated into two groups, depending on the type of analgesia during the operation. 20 patients were enrolled in each group. During the operation, patients from both groups received fentanyl in repeated doses. Patients in the studied group had an intravenous infusion of dexmedetomidine started at the time of intravenous line insertion until the beginning of surgical wound closure. Consumption of opioids and other analgesics was recorded at the end of surgery and on day 1.
Induction of anaesthesia
Aft er the insertion of an intravenous line, induction of anaesthesia was performed with fentanyl (1-2 µg/kg) and propofol (1.5-2.5 mg/kg) or ethomidat (0.2 mg/kg). For muscle relaxation rocuronium (0.6 mg/kg) was used.
Maintenance of anaesthesia
Anaesthesia depth was maintained with sevofl urane, depending on the value of the bispectral index (BIS, Vista). BIS was kept in the range suitable for surgical anaesthesia (40-55). Patients were mechanically ventilated (tidal volume 6-8 ml/kg). Normothermia and normocapnia were maintained. Mean arterial pressure was maintained within ± 25% of the basic value. If mean arterial pressure decreased more than 25% of basic value, vasoactive drugs were used (ephedrine, phenylephrine). Muscle relaxation was measured with TOF (train of four). Deep muscle block was maintained (TOF 0, posttetanic count, PTC 1-2). Before the operation, patients were randomised into two groups that varied depending on the analgesia. Prior to the surgical incision, patients from both groups received an intravenous bolus of fentanyl (1-2 µ g/kg). Additional boluses of fentanyl (1-2 µ g/kg) followed according to clinical parameters (increase in heart rate and blood pressure, sweaty skin, dilated pupils). In the studied group, an infusion of dexmedetomidine (0.3 µ g/kg/h) was started aft er intravenous line insertion and stopped at the beginning of wound closure. During the operation, fentanyl consumption was recorded. According to the measured TOF value at the end of the operation, muscle block was antagonised with neostigmin (2.5 mg) and atropine (1 mg) or sugamadex (2 mg/kg).
Postoperative period
At the end of the operation all patients received paracetamol (1 g) and an intravenous infusion of piritramide with PCA (piritramide 0.5 mg/ml, infusion rate 0.5 mg/h, bolus dose 2 mg, lock out time 30 minutes). If, in the recovery room or in the intensive care unit VAS was ≥ 3, patients fi rst received a bolus dose of piritramide from PCA and then, if necessary, an additional bolus of piritramid (3 mg) and paracetamol (1 g). Consumption of opioids, other analgesics and VAS was evaluated on the day of surgery and on the 1st postoperative day. VAS was recorded also on the 2nd postoperative day.
Statistical analysis
Our fi rst aim was to investigate the difference in general characteristics between groups with use of dexmedetomidine and without use of dexmedetomidine. Mean and standard deviation were used for description. Student's t-test was used to compare variables with normal distribution (body weight and body height) while Mann-Whitney U test was used to compare variables that were not normally distributed (age, surgery duration, opioid consumption and other analgesic consumption). Test of normality was made for each observed variable. Secondly, we investigated the infl uence of dexmedetomidine infusion, piritramide and paracetamol consumption, surgery duration, intraoperative fentanyl use, body weight and body height, age, patient ASA physical status on VAS aft er 12h with univariate linear regression model. Finally, we evaluated the infl uence of dexmedetomidine infusion and postoperative piritramide consumption on VAS (visual analogue scale) in fi rst 42h, measured every 6 hours. Complete information provided by the longitudinal data was taken into account estimating mixed-eff ects regression models, calculated by Medplot. (25) Medplot is an application for dynamic summary and analysis of longitudinal medical data. Th e application uses linear regression models for the analysis of numerical outcomes and logistic regression models for binary outcomes; a separate model is fi tted for each outcome. Th e repeated measurements for each subject are taken into account using mixed-eff ects regression models. P value of 0.050 was considered statistically signifi cant. Values were corrected for multiple comparison based on the HolmBonferroni adjustment. Power of the study (eff ect size) was calcu-
RESULTS
Forty patients randomized into two independent groups were included in the study. In Table 1 
PAIN ASSESSMENT
Pain assessment (VAS) in the postoperative period is shown in Figure 1 . Variates used in comparison, and their infl uence on VAS aft er 12 hours, are shown in Table 3 ASA, American Society of Anaesthesiologists. 
POWER OF THE STUDY
Power of the study was evaluated post hoc. Overall piritramide consumption was used in the model simulation. For simulation, Gaussian distribution of parameter was assumed. Significance of 0.05 and power of 0.8 were predicted. Calculated effect size was d=0.90. Difference among dexmedetomidine and test groups in piritramide consumption would be statistically significant if average consumption would differ for 12mg or more.
DISCUSSION
Forty patients, scheduled for radical prostatic resection, were involved in our clinical randomized prospective study. They were randomised into two groups, depending on the type of analgesia received during the operation. Intraoperatively, both groups received fentanyl in repeated doses. In the studied group dexmedetomidine infusion was started after insertion of the intravenous line and stopped at the beginning of wound closure. At the time of study completion, we found out that in the dexmedetomidine group patients were younger and operation time was shorter. Otherwise, there were no differences between the two groups in terms of body height, body weight and ASA physical status. During the operation, fentanyl consumption was recorded, and after surgery, piritramide consumption was noted. We did not find any difference between the groups. So far, few studies have been published which monitor intraoperative opioid consumption during simultaneous dexmedetomidine infusion. As in our study, Morgan and colleagues did not find any differences in intraoperative opioid consumption during simultaneous dexmedetomidine infusion (initial bolus 1 µg/ kg, followed by an infusion of 0.5µg/kg/h). (26) Also, Dong-Jian Ge did not notice reduced intraoperative opioid consumption during simultaneous dexmedetomidine infusion (0.4 µg/kg/h). (27) In contrast, reduced intraoperative opioid consumption during simultaneous dexmedetomidine use has been found in both laparoscopic and classical bariatric surgery and also in laparoscopic and classical hysterectomy. (18, 21, 28, 29) In bariatric operations, Gurbert and Bakhames used a single dose of dexmedetomidine (1 µg/kg or 0.8 µg/kg) for induction in anaesthesia, followed by intravenous infusion till the end of the operation (0.5 µg/kg/h, or 0.4 µg/ kg/h). (18) In laparoscopic and classical gynaecological operations, MC Queen-Shadfar did not find any significant correlation between the dose of dexmedetomidine and intraoperative and postoperative opioid consumption. (28) The same was proven by Tufanogullari, who used different doses of dexmedetomidine, from 0.2 µg/kg up to 0.8 µg/kg. In the same study he demonstrated a correlation between the dose of dexmedetomidine and adverse effects of dexmedetomidine on the cardiovascular system, such as hypotension, hypertension and bradycardia. He, therefore, recommended the smallest dose of dexmedetomidine 0.2 µg/kg/h in order to avoid adverse effects. (22) In our study, we did not use the initial single dose of dexmedetomidine. There are different opinions regard this topic. Some recommend it, because it probably prolongs dexmedetomidine analgesic effect postoperatively. (18, 20) With an initial dexmedetomidine bolus, efficient dexmedetomidine plasma concentration can be achieved at the beginning of the operation. Others avoid a bolus of dexmedetomidine because of possible side effects. (22, 28) Ramsay believes that the use of the initial bolus will depend on the length of anaesthesia. (30) An analgesic effect of dexmedetomidine was proven in healthy volunteers. (31) Feld and Hofer successfully used it in bariatric surgery instead of intraoperative opioids. (20, 32) In healthy volunteers,, a bolus of dexmedetomidine had a moderate analgesic effect, in comparison to fentanyl, and was found to be most effective at a dose of 0.5 µg/kg/h. (33) In many studies, the influence of intraoperative dexmedetomidine infusion on postoperative opioid and nonopioid analgesic consumption has been proven. (18) (19) (20) (21) (22) 26, 27, 29, 30, (34) (35) (36) (37) (38) Patients who received an intraoperative dexmedetomidine infusion, needed a first bolus of opioid 4 to 6 hours later than patients from the placebo group, which took the first dose of analgesic in the first hours after surgery. (26, 36) In our study, we demonstrated a lower consumption of opioids during and after surgery in a group of patients who received an intraoperative dexmedetomine infusion. The cause could be the fact that these patients were younger than those in the control group. There is evidence that age affects the need for analgesics and sedatives. (40) But in an analysis of the impact of individual factors on VAS after 12 hours, we were not able to find the impact of age and duration of the operations on the intensity of pain. Biovariability also affects pain. Results could be different if all procedures were to be performed by the same surgeon.
In our study, VAS 12 hours after surgery in the dexmedetomidine group was statistically significantly different from the control group. The effect was not detected in the follow up; it was also too small to significantly change the entire load of pain in the postoperative period. With a larger number of patients in our study or a higher-dose of intraoperative dexmedetomidine in the studied group, we might have demonstrated the impact of dexmedetomidine on opioid consumption throughout the whole postoperative period. Similarly, some studies showed that intraoperative use of dexmedetomidine did not affect the assessment of pain, using VAS, despite the fact that decreased postoperative opioid consumption was demonstrated. (22, 28, 38) 
CONCLUSIONS
In our study, we demonstrated that intraoperative use of dexmedetomidine reduces opioid consumption 12 hours after surgery. We might be able to reduce opioid consumption even during and after surgery, if we included a larger number of patients, more homogeneous groups, an initial bolus dose of dexmedetomidine and/or higher intraoperative dexmedetomidine maintenance dose. Side effects of dexmedetomidine, such as hypotension and bradycardia, were not observed in our study.
